Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Article Abstract:

The monoclonal antibody trastuzumab appears to increase the effectiveness of chemotherapy in women with breast cancer that produces excess HER2. HER2 is a growth factor receptor that can shorten survival when present in large amounts.

Author: Slamon, Dennis J., Leyland-Jones, Brian, Shak, Steven, Fuchs, Hank, paton, Virginia, Bajamonde, Alex, Fleming, Thomas (American writer), Eiermann, Wolfgang, Wolter, Janet, Pegram, Mark, Baselga, Jose, Norton, Larry
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

From the molecule to the clinic -- inhibiting HER2 to treat breast cancer

Article Abstract:

The development of a monoclonal antibody against epidermal growth factor receptor is a result of research on the molecular biology of breast cancer. When this receptor is present in larger than normal amounts, it causes a more aggressive form of the tumor. It seems to work best when given with chemotherapy.

Author: Eisenhauer, Elizabeth A.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2001
Editorial

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

Article Abstract:

The efficacy of trastuzumab, a recombinant monoclonal antibody against herceptin (HER2), along with its safety after excision of early-stage breast-cancer and completion of chemotherapy is investigated. One year of treatment with trastuzumab after chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.

Author: Ruschoff, Josef, Leyland-Jones, Brian, Baselga, Jose, Inbar, Moshe, Gelber, Richard D., Andersson, Michael, Goldhirsch, Aron, Thomssen, Christoph, Smith, Ian, Dowsett, Mitch, Bell, Richard, Cameron, David, Piccart-Gebhart, Martine J., Gianni, Luca, Barrios, Carlos H., Nitz, Ulrike, Greatorex, Victoria, Untch, Michael, Procter, Marion, Jackisch, Christian, Lichinitser, Mikhail, Istvan Lang, Iwata, Hiroji, Lohrisch, Caroline, Suter, Thomas M., Suto, Tamas, Straehle, Carolyn, McFadden, Eleanor, Dolci, Stella
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
New England States, Women, Complications and side effects, Drug therapy, Women's health, Dosage and administration, New England, Trastuzumab

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Health aspects, Breast cancer, Monoclonal antibodies, Chemotherapy
Similar abstracts:
  • Abstracts: Breast cancer. High-dose chemotherapy plus autologous bone marrow transplantation for metastatic breast cancer
  • Abstracts: Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic inflammatory process. A dual function for CD40 agonists
  • Abstracts: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism
  • Abstracts: The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer
  • Abstracts: A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.